Healthcare :: Residents urged to register for fair pharmacare
The provincial government is encouraging all British Columbians and their families to register for Fair PharmaCare if they have not done so already.
Drug
Lead :: CTFA statement on lead in lipstick
Lead is a naturally occurring element that is found everywhere in the environment. Following is the statement by John Bailey, EVP for science cosmetic, toiletry, and fragrance association on campaign for safe cosmetics report on lead in lipstick –
Almond Allergy :: Winn-Dixie stores recall mislabeled prestige chocolate ice cream
Winn-Dixie Stores, Inc. is recalling one code of its 1.75 quart (1.65 liter) cartons of “Prestige Chocolate Ice Cream” because of a potential error in packaging. Some of the products may have the correct lid identifying the product as chocolate almond, but the “tub” is identified as only chocolate.
Multiple Sclerosis :: Accentia announces investigational new drug application for Revimmune for refractory MS
Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September_26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS).
Cough :: Withdrawal of oral cough and cold medicines in Canada
Members of the Nonprescription Drug Manufacturers Association of Canada announced the voluntary withdrawal of oral cough and cold medicines intended for use in children under the age of two years. The withdrawal is a highly cautionary response to rare patterns of misuse identified during the course of a review of safety data related to children’s cough and cold medicines.
Lupus :: Patients, Physicians Invited to Lupus Education Day
Patients and physicians are invited to a Lupus Education Day to learn more about an oft-misunderstood disease, but one for which several potential new treatments are in development.
Epilepsy :: FDA approves first generic anticonvulsant drug Trileptal
The U.S. Food and Drug Administration approved the first generic versions of Trileptal (oxcarbazepine), an anticonvulsant drug. Generic oxcarbazepine is FDA-approved for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged four years and above.
Tuberculosis :: New MDR TB drugs to hit market in 4-5 years
New drugs for multi-drug resistant (MDR) tuberculosis that are expected to shorten the duration of treatment will be available in four to five years time, an expert has said.
Health :: Medical identity theft – the importance of protecting your health records
Many consumers take precautions against identity theft, but what about medical identity theft? In addition to financial peril, victims can suffer physical danger if false entries in medical records lead to the wrong treatment.
Clinical Trial :: Paving the way for future pan-European clinical trials
Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases. That was the message delivered today by the European Medical Research Councils (EMRC), the membership organisation for medical research councils across Europe based at the European Science Foundation (ESF) in Strasbourg, which is coordinating two trials in rare diseases and about to launch a review of how best to implement clinical trials that are initiated by investigators.